Histone post-translational modification: from discovery to the clinic.
Thomas
Neil R
NR
Centre for Biomolecular Sciences, School of Chemistry, University of Nottingham, University Park, Nottingham, NG7 2RD, UK. neil.thomas@nottingham.ac.uk
D000107:Acetylation; D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology* / Q000627:therapeutic use; D064127:Aurora Kinases; D001549:Benzamides / Q000494:pharmacology / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D047630:Depsipeptides / Q000494:pharmacology / Q000627:therapeutic use; D019337:Hematologic Neoplasms / Q000188:drug therapy / Q000201:enzymology; D051548:Histone Acetyltransferases / Q000037:antagonists & inhibitors* / Q000378:metabolism; D056572:Histone Deacetylase Inhibitors; D006655:Histone Deacetylases / Q000378:metabolism; D000076983:Histone Methyltransferases; D011495:Histone-Lysine N-Methyltransferase / Q000378:metabolism; D006657:Histones / Q000737:chemistry / Q000378:metabolism*; D006801:Humans; D008745:Methylation; D011487:Protein Conformation; D047428:Protein Kinase Inhibitors / Q000494:pharmacology / Q000627:therapeutic use; D011496:Protein Methyltransferases; D011499:Protein Processing, Post-Translational; D017346:Protein Serine-Threonine Kinases / Q000037:antagonists & inhibitors* / Q000378:metabolism; D011799:Quinazolines / Q000494:pharmacology / Q000627:therapeutic use
C474722:4-(4-(N-benzoylamino)anilino)-6-methoxy-7-(3-(1-morpholino)propoxy)quinazoline; D000970:Antineoplastic Agents; D001549:Benzamides; D047630:Depsipeptides; D056572:Histone Deacetylase Inhibitors; D006657:Histones; D047428:Protein Kinase Inhibitors; D011799:Quinazolines; C087123:romidepsin; D000076983:Histone Methyltransferases; D011496:Protein Methyltransferases; D011495:Histone-Lysine N-Methyltransferase; D051548:Histone Acetyltransferases; D064127:Aurora Kinases; D017346:Protein Serine-Threonine Kinases; D006655:Histone Deacetylases